Abstract: A semiconductor device according to the present disclosure includes a gate-all-around (GAA) transistor in a first device area and a fin-type field effect transistor (FinFET) in a second device area. The GAA transistor includes a plurality of vertically stacked channel members and a first gate structure over and around the plurality of vertically stacked channel members. The FinFET includes a fin-shaped channel member and a second gate structure over the fin-shaped channel member. The fin-shaped channel member includes semiconductor layers interleaved by sacrificial layers.

Abstract: Provided herein are methods for the production and identification of antibodies that bind to a desired region of a target protein.

Abstract: A liquid crystal display has position-adjustable light sources. The light sources may be lamps, LEDs, or other emissive components. The light sources, however, are movable to adjust the locations or positions of their light outputs. The light sources ride upon electromagnet carriers. When currents are applied to the electromagnet carriers, each electromagnet carrier creates a corresponding magnetic field. The magnetic fields cause neighboring electromagnet carriers to attract or to repel, depending on the magnitude/polarity of the currents. The lateral and vertical positions of the electromagnet carriers may thus be adjusted by varying their respective currents and magnetic fields. Because the light sources ride on the electromagnet carriers, the light sources may be moved to refine an image generated by the liquid crystal display. The light sources, for example, may be moved to improve white/black contracts to reduce halo-effects.

Abstract: The present invention provides anti-HtrA1 antibodies (including bispecific anti-HtrA1 anti-Factor D antibodies) and methods of making and using the same, for example, in methods of treating HtrA1-associated disorders, ocular disorders, and/or complement-associated disorders.

Abstract: A control device includes a display panel and plural key structures. Each key structure includes a keycap, an optical film layer, an elastic element, plural raised structures and a membrane switch. The optical film layer includes a light-transmissible region and a supporting region. The plural raised structures are formed on the supporting region and arranged around the light-transmissible region. The membrane switch includes an upper film layer and a lower film layer. Moreover, a light beam emitted by the display panel is transmitted upwardly through a second opening of the lower film layer, a first opening of the upper film layer, the light-transmissible region, a hollow part of the elastic element and the keycap. When the keycap is pressed down, the first circuit contact point of the upper film layer and the corresponding second circuit contact point of the lower film layer are contacted with each other.

Abstract: The invention provides anti-TIGIT (T-cell immunoreceptor with Ig and ITIM domains) antibodies and methods of using the same.

Abstract: A package assembly includes a substrate, an electronic component and a cover. The electronic component and the cover are disposed on the substrate, wherein the electronic component is located within a chamber between the cover and the substrate. A cooling liquid may be filled in a heat dissipation space of the cover, so as to dissipate the heat generated by the electronic component. Furthermore, the cooling liquid may be filled in the chamber where the electronic component is located, so as to directly dissipate the heat generated by the electronic component.

Abstract: The present invention is related to an active substance of Hericium erinaceus having a pain-relieving effect, and a pharmaceutical composition including the active substance. The active substance is prepared using the following steps: (a) inoculating a mycelium of H. erinaceus on an agar plate and incubating at 15-32° C. for 8-16 days; (b) inoculating the incubated H. erinaceus mycelia from step (a) into a medium in a flask and incubating at 20-30° C. and pH 4.5-6.5 for 3-5 days; (c) inoculating the incubated H. erinaceus mycelia from step (b) into a medium in a fermentation tank and incubating at 24-32° C. and pH 4.5-5.5 for 8-16 days to obtain a fermented medium of the H. erinaceus mycelia; and (d) desiccating the fermented medium of the H. erinaceus mycelia from step (c) to obtain the powder of the H. erinaceus mycelia, which is further purified and isolated to obtain a novel compound of H. erinaceus.

Abstract: Systems and Methods that identify the effect of motion during a medical imaging procedure. A neural network is trained to translate motion induced deviations of a coil-mixing matrix relative to a reference acquisition into a motion score. This score can be used for the prospective detection of the most corrupted echo trains for removal or triggering a replacement by reacquisition.

Abstract: An acoustic wave device includes: a substrate; a first electrode on the substrate; a piezoelectric layer on the first electrode; and a second electrode on the piezoelectric layer. A bonding interface is located between the substrate and the first electrode. The full width at half maximum (FWHM) in the X-ray diffraction pattern of the crystal plane <002> of the piezoelectric layer is between 10 arc-sec and 3600 arc-sec.

Abstract: The present invention provides anti-HtrA1 antibodies (including bispecific anti-HtrA1 anti-Factor D antibodies) and methods of making and using the same, for example, in methods of treating HtrA1-associated disorders, ocular disorders, and/or complement-associated disorders.

Abstract: Systems and Methods that identify the effect of motion during a medical imaging procedure. A neural network is trained to translate motion induced deviations of a coil-mixing matrix relative to a reference acquisition into a motion score. This score can be used for the prospective detection of the most corrupted echo trains for removal or triggering a replacement by reacquisition.

Abstract: The present invention relates to anti-CLL-1 antibodies including anti-CLL-1 antibodies comprising a CLL-1 binding domain and a CD3 binding domain (e.g., anti-CLL-1/CD3 T cell dependent bispecific (TDB) antibody) and methods of using the same.

Abstract: A method of making a semiconductor device includes comparing a thickness profile of a surface of a wafer with a reference value using a control unit. The method further includes transmitting a control signal to an adjustable nozzle based on the comparison of the thickness profile and the reference value. The method further includes rotating the adjustable nozzle about a longitudinal axis of the adjustable nozzle in response to the control signal.

Abstract: The invention provides anti-B7-H4 antibodies and immunoconjugates and methods of using the same.

Abstract: A DRAM capacitor may include a first capacitor electrode, a capacitor dielectric adjacent to the first capacitor electrode, and a second capacitor electrode adjacent to the capacitor dielectric. The first capacitor electrode may include a lower portion, an upper portion, and a step transition between the lower portion and the upper portion, a width of the upper portion of the first capacitor electrode at the step transition is less than a width of the lower portion of the first capacitor electrode at the step transition. Semiconductor devices, systems, and methods are also disclosed.

Abstract: Poly(acrylic acid)-based superabsorbent polymer (SAP) and H2O2 in a feed is converted with microwave (MW) irradiation into poly(acrylic acid) (PAA) in the product. The MW total energy used to convert SAP into PAA is less than 50 MJ/kg SAP.

Abstract: The invention provides anti-B7-H4 antibodies and immunoconjugates and methods of using the same.

Abstract: A high density plasma chemical vapor deposition (HDP CVD) chamber includes a nozzle including a base having a hollow center portion for conducting gas; a tip coupled to the base and having an opening formed therein for conducting gas from the base to the exterior of the nozzle. The HDP CVD chamber further includes a baffle positioned in a top portion of the HDP CVD chamber, wherein the baffle is equipped with an adjustable baffle nozzle.

Abstract: The present disclosure provides anti-MerTK antibodies and methods of use thereof. The methods comprise administering an anti-MerTK antibody or an immunoconjugate thereof.